Edinburgh-based venture capital firm Par Equity has invested GBP1.3m in a rapidly growing stem-cell research company that is helping pharmaceutical giants to develop new treatments for diseases including Parkinson’s and Alzheimer’s.
Censo Biotechnologies, which employs teams in Edinburgh and Cambridge, provides drug discovery services to some of the best known pharmaceutical and biotech companies in Europe, the US and Japan.
The company is a leader in technology to produce stem cells in a laboratory from a person’s skin or blood sample, which are then transformed into brain and other types of cell for drug research. It has a rapidly expanding portfolio of major drug company clients who are choosing to outsource this specialised research to Censo.
The GBP1.3m investment into Censo, part of which comes from the Scottish Investment Bank, will allow the company to expand its marketing and sales efforts and extend the commercial research services it provides to clients.
Read more HERE.
